stockrow
Saturday 7 November 2026
Export CBIO’s income statement to Excel — free account
Crescent Biopharma, Inc.
CBIO Healthcare Biotechnology
Crescent Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.8 million, up 108,340.0% from fiscal 2023.
- Revenue
- +1,038,900.0%
- EPS
- +85.0%
- Free cash flow
- −7.04%
Quarter to June 2026, against a year earlier
13.48
0.54
+4.17%
Follow CBIO
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(100.50%) | (148.37%) | (157.50%) | (101.95%) | |
| (80.95%) | (98.69%) | (140.69%) | (88.26%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(54.17%) | (67.59%) | (79.15%) | (93.04%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(2.97) | (6.95) | (2.33) | (2.35) | |
Free Cash Flow |
(49.19) | (72.42) | (70.68) | (71.85) | |
Capital Expenditures |
(0.70) | (0.89) | (1.07) | 0.83 | |
| Other line items | |||||
Cash ROIC |
(19.68%) | (17.40%) | (18.95%) | (21.46%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 11,932.52% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,434.58% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 1,328.52% | 0.00% | |
Interest Coverage |
— | (39.06) | — | — | |
Operating CF/Net income |
0.78 | 0.53 | 0.48 | 0.48 | |
Depreciation/Fixed assets |
0.05 | 0.10 | 0.16 | 0.24 | |
Capex/Depreciation |
(18.22) | (10.58) | (7.20) | 3.92 | |
Revenue per Share |
0.00 | 0.00 | 0.04 | 0.00 | |
Operating CF per Share |
(2.93) | (6.87) | (2.29) | (2.38) | |
Capex per Share |
(0.04) | (0.09) | (0.04) | 0.03 | |
Capex to Sales |
0.00 | 0.00 | 0.88 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026